219 related articles for article (PubMed ID: 15102658)
1. Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma.
Rini BI; Halabi S; Taylor J; Small EJ; Schilsky RL;
Clin Cancer Res; 2004 Apr; 10(8):2584-6. PubMed ID: 15102658
[TBL] [Abstract][Full Text] [Related]
2. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma.
Rini BI; Small EJ
J Clin Oncol; 2005 Feb; 23(5):1028-43. PubMed ID: 15534359
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.
Yang JC; Haworth L; Sherry RM; Hwu P; Schwartzentruber DJ; Topalian SL; Steinberg SM; Chen HX; Rosenberg SA
N Engl J Med; 2003 Jul; 349(5):427-34. PubMed ID: 12890841
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab for patients with metastatic renal cancer: an update.
Yang JC
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6367S-70S. PubMed ID: 15448032
[TBL] [Abstract][Full Text] [Related]
5. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.
Rini BI; Jaeger E; Weinberg V; Sein N; Chew K; Fong K; Simko J; Small EJ; Waldman FM
BJU Int; 2006 Oct; 98(4):756-62. PubMed ID: 16827904
[TBL] [Abstract][Full Text] [Related]
6. VEGF-targeted therapy in metastatic renal cell carcinoma.
Rini BI
Oncologist; 2005 Mar; 10(3):191-7. PubMed ID: 15793222
[TBL] [Abstract][Full Text] [Related]
7. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.
Rini BI; Halabi S; Rosenberg JE; Stadler WM; Vaena DA; Archer L; Atkins JN; Picus J; Czaykowski P; Dutcher J; Small EJ
J Clin Oncol; 2010 May; 28(13):2137-43. PubMed ID: 20368558
[TBL] [Abstract][Full Text] [Related]
8. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.
Choueiri TK; Vaziri SA; Jaeger E; Elson P; Wood L; Bhalla IP; Small EJ; Weinberg V; Sein N; Simko J; Golshayan AR; Sercia L; Zhou M; Waldman FM; Rini BI; Bukowski RM; Ganapathi R
J Urol; 2008 Sep; 180(3):860-5; discussion 865-6. PubMed ID: 18635227
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab as a treatment option in advanced renal cell carcinoma: an analysis and interpretation of clinical trial data.
McDermott DF; George DJ
Cancer Treat Rev; 2010 May; 36(3):216-23. PubMed ID: 20116176
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
Escudier B; Pluzanska A; Koralewski P; Ravaud A; Bracarda S; Szczylik C; Chevreau C; Filipek M; Melichar B; Bajetta E; Gorbunova V; Bay JO; Bodrogi I; Jagiello-Gruszfeld A; Moore N;
Lancet; 2007 Dec; 370(9605):2103-11. PubMed ID: 18156031
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab: direct anti-VEGF therapy in renal cell carcinoma.
Escudier B; Cosaert J; Pisa P
Expert Rev Anticancer Ther; 2008 Oct; 8(10):1545-57. PubMed ID: 18925847
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.
Rini BI; Halabi S; Rosenberg JE; Stadler WM; Vaena DA; Ou SS; Archer L; Atkins JN; Picus J; Czaykowski P; Dutcher J; Small EJ
J Clin Oncol; 2008 Nov; 26(33):5422-8. PubMed ID: 18936475
[TBL] [Abstract][Full Text] [Related]
13. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.
Na X; Wu G; Ryan CK; Schoen SR; di'Santagnese PA; Messing EM
J Urol; 2003 Aug; 170(2 Pt 1):588-92. PubMed ID: 12853836
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab: in first-line treatment of advanced and/or metastatic renal cell carcinoma.
Frampton JE; Keating GM
BioDrugs; 2008; 22(2):113-20. PubMed ID: 18345708
[TBL] [Abstract][Full Text] [Related]
15. Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies.
Golshayan AR; Brick AJ; Choueiri TK
Future Oncol; 2008 Feb; 4(1):85-92. PubMed ID: 18241003
[TBL] [Abstract][Full Text] [Related]
16. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.
Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A
Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414
[TBL] [Abstract][Full Text] [Related]
17. FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma.
Summers J; Cohen MH; Keegan P; Pazdur R
Oncologist; 2010; 15(1):104-11. PubMed ID: 20061402
[TBL] [Abstract][Full Text] [Related]
18. The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer.
George DJ; Kaelin WG
N Engl J Med; 2003 Jul; 349(5):419-21. PubMed ID: 12890838
[No Abstract] [Full Text] [Related]
19. Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia.
Gunningham SP; Currie MJ; Han C; Turner K; Scott PA; Robinson BA; Harris AL; Fox SB
Cancer Res; 2001 Apr; 61(7):3206-11. PubMed ID: 11306510
[TBL] [Abstract][Full Text] [Related]
20. Advanced renal cell carcinoma: current and emerging management strategies.
Escudier B
Drugs; 2007; 67(9):1257-64. PubMed ID: 17547470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
